Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous RRx-001 in Advanced Solid Tumors
NCT02096341Phase 1Terminated
- Sponsor
- EpicentRx
- Start
- Apr 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nibrozetone in solid tumor and lymphoma, sponsored by EpicentRx. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events at 10 weeks. Started Apr 2014; status: terminated.
02
Drugs
Nibrozetone
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02096341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096341.